ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities
During the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13…
Browsing: ASH
ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back
Many children with ALL have a good outcome of their disease. After two years of chemotherapy…
ASH 2022: CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial
A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of…
ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and lenalidomide shows clinical activity in RRMM
According to the results of the phase 1b MajesTEC-2 study, the immune-based triplet therapy regimen of teclistamab-cqyv, a…
ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma
In an early-phase trial, nearly three-quarters of patients who received talquetamab, a first-in-class experimental immunotherapy…
ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma
Patients receiving the anti-CD38 monoclonal antibody isatuximab in addition to the standard three- component induction…
ASH 2021: Older adults at high risk for multiple myeloma precursor condition may benefit from screening
The first results from the largest screening study yet conducted in the United States of…